Ultrasound plus biomarker finds early-stage ovarian cancer, saving lives
Ultrasound plus proteomic analysis of blood samples may help physicians identify early-stage ovarian cancer and save the lives of many women, according to researchers from the Mount Sinai School of Medicine and Vanderbilt University.
Ultrasound plus proteomic analysis of blood samples may help physicians identify early-stage ovarian cancer and save the lives of many women, according to researchers from the Mount Sinai School of Medicine and Vanderbilt University.
More than 21,500 women annually are diagnosed with the disease, 67% of them at an advanced stage. If ovarian cancer is detected at an early stage, survival is greater than 90%.
Contrast ultrasound may help confirm or eliminate the possibility that biomarkers can accurately detect early-stage ovarian cancer. Contrast agents may significantly improve the diagnostic ability of ultrasound to identify early microvascular changes known to be associated with earlystage ovarian cancer, said Dr. Arthur C. Fleischer, a coauthor of the study and a professor of radiology at Vanderbilt.
“Separately, proteomics and ultrasound are of limited value as early detection tools,” he said. “However, in combination, we will likely be able to shift from an era of diagnosing advanced stage ovarian cancer to that of early-stage disease, and save the lives of many women.”
Philips Launches Flash 5100 Point-of-Care Ultrasound System
June 17th 2025Offering a combination of intuitive touchscreen controls and enhanced image clarity, the portable Flash 5100 POC ultrasound platform reportedly facilitates confident and rapid assessment in emergency radiology and critical care settings.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
